The team behind Aimovig® is committed to helping keep customers and patients informed. Click here for more information related to Aimovig® and COVID-19.

Indication

Aimovig® is indicated for the preventive treatment of migraine in adults.

Indication
Prescribing Information
  • Prescribing Information
    (ENGLISH)
  • Información de Prescripcion
    (SPANISH)
  • Patient Product Information
    (ENGLISH)
  • Información Para el Paciente
    (SPANISH)
  • Instructions for Use 70 mg/mL
    (ENGLISH)
  • Instrucciones de Use 70 mg/mL
    (SPANISH)
  • Instructions for Use 140 mg/mL
    (ENGLISH)
  • Instrucciones de Use 140 mg/mL
    (SPANISH)
Resources to Start Aimovig®
Indication
Important Safety Information
Visit Patient Site
For US Health Care Professionals Only
Aimovig Aimovig
For US Health Care Professionals Only
Home Home
Menu
  • Prescribing Information
    • Prescribing Information
      (ENGLISH)
    • Información de Prescripcion
      (SPANISH)
    • Patient Product Information
      (ENGLISH)
    • Información Para el Paciente
      (SPANISH)
    • Instructions for Use 70 mg/mL
      (ENGLISH)
    • Instrucciones de Use 70 mg/mL
      (SPANISH)
    • Instructions for Use 140 mg/mL
      (ENGLISH)
    • Instrucciones de Use 140 mg/mL
      (SPANISH)
  • Efficacy
  • Safety
  • Dosing
  • Resources to Start Aimovig®
Home

you are now leaving aimovighcp.com

You are about to leave the aimovighcp.com website and enter a website operated by a third party. Amgen & Novartis are not responsible for and do not endorse or control the content contained on this third-party website.

Continue

Site Map

  • Home
  • Efficacy
    • MMDs: Ph 3 EM Months 4 to 6
    • MMDs: Ph 2 EM Year 4.5
    • Response Rates: ≥50% Response
    • Response Rates: ≥75% Response
    • Prior Preventives: Monthly Migraine Days
    • Prior Preventives: Subgroup Population
  • Safety
    • Pooled Ph 3 Pivotal Studies
    • Ph 3 EM ATP at Year 1
    • Ph 2 EM at Year 4.5
  • Dosing
  • Resources to Start Aimovig®
  • AHS Guidance for Treatment Course
    • AHS Guidance for Anti-CGRPs
  • COVID-19 FAQs
  • Indication
  • Prescribing Info
    • Prescribing Information (English)
    • Información de Prescripcion (Spanish)
    • Patient Product Information (English)
    • Información Para el Paciente (Spanish)
    • Instructions for Use 70 mg/mL (English)
    • Instrucciones de Use 70 mg/mL (Spanish)
    • Instructions for Use 140 mg/mL (English)
    • Instrucciones de Use 140 mg/mL (Spanish)
  • Visit Patient Site
  • Amgen
  • Novartis
  • Contact
  • Privacy Statement
  • Terms of Use
  • Ad Choices

Important Safety Information

Contraindication: Aimovig® is contraindicated in patients with serious hypersensitivity to erenumab-aooe or to any of the excipients. Reactions have included anaphylaxis and angioedema.

Hypersensitivity Reactions: Hypersensitivity reactions, including rash, angioedema, and anaphylaxis, have been reported with Aimovig® in post marketing experience.

Indication

Aimovig® is indicated for the preventive treatment of migraine in adults.

Important Safety Information

Contraindication: Aimovig® is contraindicated in patients with serious hypersensitivity to erenumab-aooe or to any of the excipients. Reactions have included anaphylaxis and angioedema.

Hypersensitivity Reactions: Hypersensitivity reactions, including rash, angioedema, and anaphylaxis, have been reported with Aimovig® in post marketing experience. Most reactions were not serious and occurred within hours of administration, although some occurred more than one week after administration. If a serious or severe reaction occurs, discontinue Aimovig® and initiate appropriate therapy.

Constipation with Serious Complications: Constipation with serious complications has been reported following the use of Aimovig® in the postmarketing setting. There were cases that required hospitalization, including cases where surgery was necessary. The onset of constipation was reported after the first dose in a majority of these cases, but patients also reported later on in treatment. Aimovig® was discontinued in most reported cases. Constipation was one of the most common (up to 3%) adverse reactions reported in clinical studies.

Monitor patients treated with Aimovig® for severe constipation and manage as clinically appropriate. Concurrent use of medications associated with decreased gastrointestinal motility may increase the risk for more severe constipation and the potential for constipation-related complications.

Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of Aimovig® in the postmarketing setting. Many of the patients had pre-existing hypertension or risk factors for hypertension. There were cases requiring pharmacological treatment and, in some cases, hospitalization. Hypertension may occur at any time during treatment but was most frequently reported within seven days of dose administration. In the majority of the cases, the onset or worsening of hypertension was reported after the first dose. Aimovig® was discontinued in many of the reported cases.

Monitor patients treated with Aimovig® for new-onset hypertension, or worsening of pre-existing hypertension, and consider whether discontinuation of Aimovig® is warranted if evaluation fails to establish an alternative etiology.

Adverse Reactions: The most common adverse reactions in clinical studies (≥ 3% of Aimovig®-treated patients and more often than placebo) were injection site reactions and constipation.

Please see Aimovig® full Prescribing Information.

AMGEN NOVARTIS CONTACT SITE MAP PRIVACY STATEMENT TERMS OF USE ad choices

© 2020 Amgen Inc. All rights reserved.
This website is intended for US health care professionals only.
amgen-logo novartis-logo